Clinical trial
Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or…
NCT00003515 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003515 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Primitive Neuroectodermal Tumor Outside the Central Nervous System |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primitive Neuroectodermal Tumor |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 1 |
| Start date | Dec 12, 1996 |
| Primary completion | Jan 3, 1997 |
| Completion | Jan 3, 1997 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: